Teresa Knoop speaks to ecancer at ONS 2019 about how the use of PARP inhibitors has changed.

She explains that clinical trials have so far indicated that PARP inhibitors may be more promising in treating breast and ovarian cancers with BRCA gene mutations.

Teresa concludes by saying that more research is needed to discover if PARP inhibitors are useful in treating cancers without known mutations or to discover potential combination strategies.

This programme has been supported by an unrestricted educational grant from Pfizer.

свернуть